Nykredit A S Takes Position in Biogen Inc. $BIIB

Nykredit A S bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 41,734 shares of the biotechnology company’s stock, valued at approximately $9,017,000.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Biogen in the 2nd quarter valued at approximately $3,453,878,000. Primecap Management Co. CA acquired a new stake in shares of Biogen during the second quarter worth approximately $3,274,304,000. Geode Capital Management LLC increased its stake in shares of Biogen by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after buying an additional 130,618 shares during the last quarter. Wellington Management Group LLP raised its holdings in Biogen by 5.3% in the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after acquiring an additional 155,828 shares in the last quarter. Finally, Norges Bank acquired a new stake in Biogen in the fourth quarter valued at $464,408,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Down 1.6%

Biogen stock opened at $220.83 on Friday. The firm’s 50-day moving average is $209.53 and its 200-day moving average is $196.62. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. Biogen Inc. has a 1 year low of $135.39 and a 1 year high of $225.80. The company has a market cap of $32.63 billion, a P/E ratio of 39.08, a PEG ratio of 2.44 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts expect that Biogen Inc. will post 12.39 earnings per share for the current year.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Long-term Dravet syndrome data support zorevunersen. Biogen and Stoke Therapeutics reported four-year Phase 1/2a extension data showing durable seizure reductions, including reductions in severe seizure types associated with sudden unexpected death in epilepsy, as well as continued improvements in cognition, behavior and quality of life. The results strengthen the potential for zorevunersen to become a disease-modifying treatment, though it remains investigational. Stoke and Biogen unveil long-term zorevunersen data
• Positive Sentiment: LEQEMBI gained a major China regulatory approval. China’s National Medical Products Administration approved the once-weekly subcutaneous autoinjector formulation of LEQEMBI for initiation treatment in early Alzheimer’s disease. At-home dosing could improve patient convenience, reduce infusion-center burdens and broaden adoption in a large and growing market. Eisai leads development and commercialization, with Biogen sharing economics under their collaboration. Biogen and Eisai announce China LEQEMBI approval
• Positive Sentiment: U.S. patients can now access weekly at-home LEQEMBI injections. Biogen and Eisai launched LEQEMBI IQLIK in the United States for eligible early Alzheimer’s patients, offering initiation and maintenance treatment through a pre-filled syringe or autoinjector. The new delivery option may lower barriers to treatment and support future product demand.
• Neutral Sentiment: Investors are assessing valuation after a strong rally. A valuation analysis argued that BIIB could be materially below estimated discounted-cash-flow value, but also noted that earnings-based multiples make the shares appear expensive. This conflicting signal may be contributing to caution after the stock’s substantial one-year gain.
• Negative Sentiment: Execution and safety risks remain. Zorevunersen’s data are from open-label early-stage studies and require confirmation in later trials. LEQEMBI’s subcutaneous formulation also carries injection-related reactions and still requires MRI monitoring for amyloid-related imaging abnormalities, potentially limiting uptake.

Analysts Set New Price Targets

BIIB has been the subject of several recent analyst reports. Bank of America decreased their price objective on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a report on Tuesday, July 21st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Biogen in a research report on Monday, July 13th. Wedbush lifted their price target on Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, July 30th. Morgan Stanley boosted their price objective on Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Finally, UBS Group upped their price objective on Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.50.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.